Introduction: Prolactinomas are usually benign and respond well to dopamine agonist
therapy. However, approximately 20% are resistant, and 10% behave aggressively and …

Objective Morbid obesity may be related to a prolactinoma, although uncommon, and can
lead to adverse effects like insulin resistance and metabolic syndrome. Recent research …

Background/Purpose: A prolactinoma is the most common pituitary adenoma, but it is
relatively rare in childhood and adolescence. There is only limited research about the …

Prolactinoma is a rare pituitary adenoma secreting prolactin. Studies on diagnostics,
treatment, and prognosis in pediatric prolactinoma patients are rare. We analyzed clinical …

Context The improved remission and complication rates of current transsphenoidal surgery
warrant reappraisal of the position of surgery as a viable alternative to dopamine agonists in …

As ErbB signaling is a determinant of prolactin synthesis, role of ErbB receptors was tested
for prolactinoma outcomes and therapy. The objective of this study was to characterize ErbB …

Objective To report the clinical presentation, management and outcomes of young patients
with prolactinomas (< 20 years) and conduct a systematic review and meta‐analysis …

105 march 2010, vol. 68, no 3 rate similar to that of immunoglobulins. Depending on the
immunoassay used, macro prolactinaemia accounts for up to 25% of biochemically …

The authors provide an update on the clinical manifestations and diagnostic challenges of
prolactinomas. Prolactinomas are the most common pituitary adenoma seen in clinical …

Dopamine agonists (DAs) are well recognized as the first-line therapy for prolactinomas due
to their efficacy in achieving tumoral shrinkage and normoprolactinemia. However, it …